Teva Pharmaceutical Industries Ltd. TEVA announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of ...

In the rapidly changing landscape of migraine therapeutics, providers are faced with the challenge of navigating unfamiliar waters. Parenteral therapies targeting calcitonin gene-related peptide (CGRP ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the autoinjector device for AJOVY ® ...

Dublin, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The "Global CGRP Inhibitor Market (2023 Edition): Analysis By Treatment (Preventive, Acute), Route of Administration (Oral, Nasal, Intravenous), By End-User, ...

Most patients with migraine are women, and this observation is reflected in clinical studies. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin ...